FDA approves first CELMoD agent, with Dana-Farber helping advance its development
August 14, 2026
August 14, 2026
BOSTON, Massachusetts, Aug. 14 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:
* * *
FDA approves first CELMoD agent, with Dana-Farber helping advance its development
*
The U.S. Food and Drug Administration has approved iberdomide in combination with daratumumab and dexamethasone for patients with relapsed or refractory multiple myeloma, making it the first approved cereblon E3 ligase modulator (CE . . .
* * *
FDA approves first CELMoD agent, with Dana-Farber helping advance its development
*
The U.S. Food and Drug Administration has approved iberdomide in combination with daratumumab and dexamethasone for patients with relapsed or refractory multiple myeloma, making it the first approved cereblon E3 ligase modulator (CE . . .